A collaborative study by researchers from the U.S. and the Netherlands has introduced the Metabolic Dysbiosis Score (MDS)—a novel biomarker that uses gut-derived metabolites to assess mortality risk in critically ill patients. Published in Science Advances, the study demonstrates how gut health could guide life-saving interventions in intensive care units.
Identifying Risk Through Fecal Metabolites
As reported by medicalxpress, the team collected fecal samples from 196 patients admitted to a medical ICU for non-COVID-19 respiratory shock or failure. Using shotgun metagenomic sequencing and high-precision mass spectrometry, they analyzed the microbiome composition and levels of 13 key fecal metabolites. Based on these profiles, they developed the MDS, which accurately predicted patients at high risk of 30-day mortality.
Gut Dysbiosis and Its Impact on Health
The gut microbiome plays a critical role in overall health, and its disruption—especially in ICU settings—can lead to metabolic imbalance. Antibiotic use and critical illness often reduce microbial diversity, allowing harmful bacteria like Enterococcus and Enterobacterales to dominate. These imbalances can impair gut function, increase infection risk, and worsen outcomes.
New Biomarker Outperforms Traditional Indicators
Interestingly, the study found that a high MDS (>7.5) raised the risk of 30-day mortality by 8.66 times. In contrast, traditional microbiome diversity markers and Enterococcus abundance showed no significant association with mortality. This underscores the MDS’s potential as a more reliable indicator.
Looking Ahead
The researchers emphasized that fecal metabolic dysbiosis may be a treatable trait. The MDS could help clinicians identify vulnerable patients and tailor timely interventions. However, they also cautioned that the findings, while promising, need validation through larger, multi-center studies before the MDS can be adopted as a diagnostic tool in clinical practice.